Session Type: ACR Poster Session C
Session Time: 9:00AM-11:00AM
Background/Purpose: Early diagnosis of psoriatic arthritis (PsA) is critical to prevent poor outcome. Several validated screening questionnaires have been developed to identify PsA patients in the psoriasis population in dermatology and general practice settings. We aimed to test the performance of the CONTEST questionnaire in diagnosing PsA compared to the other existing tools.
Methods: Psoriasis patients from a primary dermatology clinic and combined rheumatology-dermatology clinics in one medical center completed the Psoriatic Arthritis Screening and Evaluation tool (PASE), Toronto Psoriatic Arthritis Screen2 (ToPAS2), Psoriasis Epidemiology Screening Tool (PEST) and Early Arthritis for Psoriatic Patients(EARP) questionnaires prior to rheumatologic evaluation. A composite score was calculated by abstracting the score of each discriminatory item from the original tools that constitute the CONTEST questionnaire. The results were compared to the diagnosis of PsA according to CASPAR criteria. The sensitivity and specificity of the different instruments were calculated using the defined cut offs of each instrument. The association between questionnaires’ performance and age, gender, level of education, and systemic therapy was assessed using non-parametric statistics as appropriate.
Results: Of the 208 patients screened, 108 fulfilled the CASPAR criteria. The sensitivity of PASE, ToPAS2, PEST and EARP and CONTEST was 57.9%,60%,79.4%,78.5% and 70%,respectively.The specificity was 93%,93.2%,94.9%,91.8% and 91%,respectively. The performance of the tools was not affected by age, gender or educational level. Patients on systemic therapy obtained significantly higher scores on the PASE (p=0.03), PEST (p=0.003), EARP (p=0.01) and CONTEST (p=0.0001) questionnaires, but not on the ToPAS2.
Conclusion: All screening questionnaires are helpful in excluding PsA, but cannot serve as substitutes for clinical diagnosis. The CONTEST questionnaire had no additive diagnostic value to the other screening questionnaires of which the PEST had the highest sensitivity and specificity.
To cite this abstract in AMA style:Haddad A, Feld J, Eder L, Lavi I, Zlazhover O, Zisman D. Appraisal of the Contest Questionnaire in the Screening for Psoriatic Arthritis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/appraisal-of-the-contest-questionnaire-in-the-screening-for-psoriatic-arthritis/. Accessed September 24, 2023.
« Back to 2017 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/appraisal-of-the-contest-questionnaire-in-the-screening-for-psoriatic-arthritis/